Bone Marrow Suppression
Patients with liver disease are at an increased risk of bone marrow suppression while using Albendazole. Such patients may have an increased risk of fatality due to the reduced number of blood granulocytes (Granulocytopenia). Albendazole should be discontinued if there is a significant decrease in blood cell count.
Pregnant women and women who want to conceive are at an increased risk when using this medicine. Use of this medicine in pregnant women may cause harm to the fetus. Use effective birth control measures for the duration of Albendazole treatment, and it should be continued for one month even after the end of therapy. Discontinue the use of Albendazole if a patient becomes pregnant.
Patients with tapeworm infection that affects the brain, muscles and body tissues (neurocysticercosis) are at an increased risk when using Albendazole. These patients may develop seizures
and increased pressure within the brain. Such patients should take steroid
and anticonvulsant therapy to prevent brain related symptoms.
Tapeworm Infection of the Eye
Patients with the tumor
in the eyes (retinal lesions) are at an increased risk. Albendazole kills the parasite and can cause retinal damage. Proper eye check-up should be done before the start of the Albendazole therapy.
Patients with increased liver enzymes are at an increased risk when using this medicine. Such patients are at an increased risk of liver damage and bone marrow suppression. Discontinue the use of Albendazole if liver enzymes get significantly increased or if there is a decrease in blood cell count.
Patient with parasitic infection which affects the liver, lungs, and peritoneum (hydatid disease) should be assessed properly before starting the Albendazole therapy.